Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairment, and it is strongly associated with acetylcholinesterase (AChE) activity. In the present study, a comprehensive in silico workflow was employed to identify potential AChE inhibitors using Rosmarinic Acid (RA) and Ursolic Acid (UA) as natural reference scaffolds for ligand-based similarity screening, while Donepezil, Galantamine, and Rivastigmine were employed as clinically approved control references for comparative docking analysis. Ligand-based similarity screening of the ZINC database yielded approximately 800 structurally related compounds, which were subsequently evaluated for binding activity via molecular docking with AutoDock Vina. Among the screened compounds, ZINC000014690028, ZINC000017175753, ZINC000013546994, and ZINC000253617523 demonstrated notable binding affinities ranging from -11.05 to -13.00 kcal/mol compared with the reference ligands. ADME/T profiling demonstrated generally favorable pharmacokinetic characteristics for selected compounds; however, some candidates exhibited predicted hepatotoxicity, CYP inhibition liabilities, and comparatively lower drug-likeness, highlighting the need for further optimization and experimental validation. Molecular dynamics (MD) simulations of 100 ns were performed using GROMACS 2025.2; additional MD simulations supported the dynamic stability of the protein-ligand complexes through analyses of RMSD, RMSF, radius of gyration, and hydrogen bonds. Among the newly identified ZINC compounds, ZINC000014690028 exhibited the most favorable MM-PBSA binding free energy (ΔG bind = -23.14 kcal/mol ) , whereas Ursolic Acid showed the lowest overall ΔGbind among all evaluated compounds. While ZINC000253617523 showed comparatively stable energetic behavior with lower energy fluctuation throughout the simulation trajectory. Notably, ZINC000014690028, derived from the RA scaffold, and ZINC000253617523, derived from the UA scaffold, maintained favorable binding orientations with minimal conformational fluctuations throughout the simulation period. Collectively, these findings identify ZINC000014690028 and ZINC000253617523 as computationally prioritized AChE-binding candidates for further optimization and experimental validation in the development of Alzheimer's disease therapeutics.
No takes yet. Share an insight, caveat, or question.
Hadiyal et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: